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As opportunistic infections and acquired immune deficiency syndrome (AIDS)-relatedcancers are decreasing in the human immunodeficiency virus (HIV)-infected popula-
tion since the advent of highly active antiretroviral therapy (HAART), new causes of
morbidity and mortality are emerging, such as cardiovascular diseases and non-AIDS-
defining cancers (NADCs).1–4 The general aging of the HIV-infected populations in
resource-rich settings, because of an increasing life expectancy approaching that of the
general population in some successfully treated groups, also explains this shift to
nonopportunistic diseases.5,6 In resource-rich setting studies, lung cancer has the highest
incidence rate of all NADCs,3,7 and despite the advent of HAART, its incidence rate
remains increased in comparison with the non-HIV-infected population. The review by
Pakkala and Ramalingam8 focuses on epidemiological, clinical, and management of lung
cancers in HIV-infected patients and helps us to disentangle future perspectives of
research. This review underscores the increased incidence and the clinical particularities
of lung cancer in the HIV-infected population in comparison with the HIV-negative
counterparts, including an increased proportion of advanced stages III and IV and young
age at diagnosis, as well as its dismal prognosis.
The reasons of an increased incidence in the rate of lung cancer in the HIV-infected
population in comparison with their uninfected counterparts have been approached in this
review. One factor is the increased prevalence of smoking in the HIV-infected popula-
tions: in different observational cohorts, the rate of chronic smoking history has been
evaluated as more than 50%, outnumbering the proportion of smokers in the general
population.9 However, this characteristic, although essential in the triggering of lung
cancer in the HIV-infected population, is insufficient to completely explain the increased
incidence, because multivariate studies adjusted on smoking status, age, and gender have
found a persistent increased risk of lung cancer.10–12
The most important factor explaining increased incidence of lung cancer in HIV-
infected patients is probably the intensity and duration of immune deficiency. Grulich et
al.13 found a significantly and similar standardized increased ratio in lung, trachea, and
bronchus cancer in comparison with the general population in HIV-infected population
and solid organ transplant recipients in a meta-analysis of population-based cohorts
(respective standardized increased ratio of 2.72 [1.91–3.87] and 2.18 [1.85–2.57]),
immunodeficiency being the only common factor between these two populations. It is now
well established that the intensity of CD4 depletion is an important factor. The Clinical
Epidemiology Group of the FHDH-ANRS CO4 cohort correlated risk of lung cancer with
the latest levels of CD4 strata7 in more than 52,278 subjects and showed a progressive
increase of incidence for each lower strata of CD4: odd ratios ranged from 8.5 (4.3–16.7)
for the CD4 strata of50 cells/l to 2.2 (1.3–3.6) for the CD4 strata of 350 to 500 cells/l
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in comparison with HIV-infected patients with 500 CD4
cells/l. Moreover, the French HIV-infected Aquitaine co-
hort found a significant association between the cumulative
duration of CD4 immunodeficiency and occurrence of
NADCs.14 In this study, HIV-infected patients were enrolled
between 1998 and 2006, and 251 first malignancies were
declared in 4194 patients (22,389 person-years). A higher
incidence of NADCs (144 cases) was independently associ-
ated with longer and current exposure to a CD4 cell count
500 cells/l (hazard ratio 1.13 per year [p 0.01] and 2.07
[p  0.01], respectively) but not with plasma HIV RNA
level. The rapid evolution and the high proportions of stage
IV at lung cancer diagnosis in the HIV-infected population
also pleads for an increased tumor proliferation in HIV-
infected populations, which may be fostered by cellular
immunodeficiency.15 Recent phase I/II clinical trials have
also highlighted the potential survival benefit of cellular
immune responses to antitumoral vaccination in the non-
HIV-infected population with non-small cell lung cancer
(NSCLC), indicating that immune deficiency may induce
lack of tumoral control.16,17
Other factors potentially implicated in the increased
incidence of lung cancer in the HIV-infected population need
to be further explored. Oncogenic viruses are tumor triggers
in AIDS-defining cancers, such as Epstein-Barr virus for
non-Hodgkin Lymphoma, human papillomavirus for cervical
cancers, and human herpesvirus 8 in Kaposi sarcoma, induc-
ing cellular proliferation in the context of chronic immuno-
deficiency. Some NADCs are also virologically induced, such
as hepatitis C virus and hepatocarcinoma, human papilloma-
virus and anal cancer or Epstein-Barr virus, and Hodgkin
lymphoma. The search of an oncogenic virus in lung cancer
cells in the HIV-infected population has remained negative to
this day.18,19 HIV, although theoretically potentially an onco-
genic virus, has never been associated by itself with the
occurrence of NADCs.
Clinical research is warranted in the HIV-infected pop-
ulation at risk or with lung cancer to improve prophylaxis and
clinical management. Studies could concentrate on optimal
strategies for smoking interruption. Clinical studies on com-
puted tomography screening of lung cancer in HIV-infected
subjects at highest risk of lung cancer could also be justified.
Studies concerning optimal therapeutic management strate-
gies of HIV-infected patients with lung cancer are also
warranted. As mentioned in the review, there are no prospec-
tive clinical data on interactions between chemotherapy and
antiretroviral therapy. One review focuses on potential inter-
actions between cytochrome P450 metabolized antineoplastic
drugs and protease inhibitors,20 but the data are deduced from
case reports as well as antineoplastic and antiretroviral phar-
macokinetic characteristics. Another retrospective study of
40 HIV-infected subjects with NSCLC and treated with
antineoplastic chemotherapy from the Dat’Aids cohort
showed that zidovudine and protease inhibitor use were
associated with grade IV hematological toxicities, primarily
through CYP450 inhibition and additive toxicities (personal
data, paper submitted). Two other retrospective studies
showed that pursuing HAART after NSCLC diagnosis sig-
nificantly increased survival in HIV-infected subjects by 74%
(HR  0.26, 95% CI: 0.09–0.74)21 and by 60% (HR  0.4,
95% CI: 0.2–0.9)22 in multivariate analysis. Specific genetic
pathways in NSCLC, potentially inducing specific therapeu-
tic strategies, could be further assessed, such as prevalence of
epidermal growth factor receptor mutation, K-Ras mutation,
and EML4/ALK translocation. Increased genetic instability
has been objectified in one study in lung cancer histologic
analysis in HIV-positive and -negative patients, although the
significance of this result needs to be explored.19
Lung cancer in the HIV-infected population is an
emerging NADC. An improvement in prognosis is clearly
needed. Prevention, early diagnosis, and treatment need to be
further addressed in studies specifically designed for this
particular population, as specific physiopathologic pathways
probably explain its increased incidence and aggressiveness.
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